Pretty groundbreaking news here at Novamind! Recently Blue Cross Blue Shield agreed to cover intravenous ketamine for depression, despite still being off-label. This sets an exciting precedent going forward because it sends a strong signal that payors are interested in more effective treatments for mental health conditions as supporting research emerges. Feel free to check out the full article at the link below.
